Orca Bio在萨克拉门托扩建了新的最先进的制造工厂

Contact:
米歇尔. 威拉德
Chief Public Affairs Officer
(916) 287-9072
mwillard@dltq.net

09/08/2022

Leading Bay Area Biotech Company Expands to State Capital of California

Orca Bio扩大制造能力，以开发和商业化其精密细胞疗法

-新的最先进的生产设施旨在确保Orca Bio的后期临床开发和商业产品管道的可靠生产

– The 100,000-square-foot facility is located in Metro Air Park, Sacramento –

SACRAMENTO, Calif. – Orca Bio, 这是一家后期生物技术公司，正在开发用于治疗癌症的高精度细胞疗法, genetic blood disorders and autoimmune diseases, 宣布扩大其现有的制造能力，建设新的100个,000-square-foot commercial facility in Sacramento. 该设施将支持Orca Bio精密细胞疗法的后期临床开发和商业化, including Orca-T, which is currently being evaluated in a Phase 3 registrational trial.

The 大萨克拉门托经济委员会 (GSEC) worked with community partners including Sacramento County, SMUD, Buzz Oates, 十大网投官方入口大学戴维斯分校和萨克拉门托州立大学帮助虎鲸生物公司在大萨克拉门托地区扩张, specifically at Metro Air Park in Sacramento.

“我们很高兴Orca Bio决定在Metro Air Park扩建并建造一个新的制造工厂,” GSEC Board Chair and President & CEO of Buzz Oates Larry Allbaugh said. “As we look at our development footprint at the premier industrial business park, we are becoming more innovative with our adaptable uses for companies. 我们努力确保Orca Bio在这里拥有生产细胞疗法所需的一切，因为我们重视大萨克拉门托地区这些类型的生命科学工作.”

“As an elected leader in Sacramento County, it’s important we help companies efficiently get through the permitting process,” Sacramento County Supervisor Phil Serna said. “我们的官方十大网投网址团队高效地帮助Orca Bio通过了许可程序，并与公用事业部门合作，迅速开始建设他们的建筑. Metro Air Park is an important industrial development for our county, 这就是为什么我们花了很多时间来确保它的基础设施计划是面向未来的业务增长.”

Orca Bio的新工厂位于萨克拉门托新开发的地铁航空公园，毗邻萨克拉门托国际机场, enabling direct shipping access to transplant centers across the U.S. It is also near Orca Bio’s existing clinical manufacturing building. 该设施专门用于制造精确的细胞疗法，旨在用健康的血液和免疫系统取代癌变的血液和免疫系统. It touts digitally enabled modular production suites, which are adjustable for future growth, quality control laboratories, warehouse space and offices. 该项目于2021年8月开始建设，计划于今年晚些时候完工. 该设施预计将在2023年上半年全面验证并投入使用.

“Throughout the clinical development of our products, 我们已经证明了在快速周转时间内可靠地制造和提供高精度细胞疗法的能力, regardless of donor and patient location,” said Ivan Dimov, Ph.D., Co-founder and Chief Executive Officer of Orca Bio. “这个新设施将进一步增强我们的能力，为大规模患者提供紧急和无缝的治疗, while meeting the highest quality and regulatory standards.”

Orca Bio的独特方法使用精确的细胞选择技术来识别1000亿个供体细胞中的一小部分，这些细胞可能对患者有治疗作用. 然后，这些细胞被制造成潜在的治愈性细胞疗法，旨在最大限度地提高治疗效果，并显著限制治疗相关风险. Orca Bio recently announced Precision-T, 评估Orca-T治疗急性髓性白血病(AML)的关键3期研究, acute lymphocytic leukemia (ALL) and high-risk myelodysplastic syndromes (MDS), is open for enrollment at leading transplant centers across the U.S.

About Orca-T
Orca-T是一种研究性的高精度同种异体细胞疗法，包括输注含有调节性t细胞, 传统t细胞和CD34+干细胞来源于相关或非相关匹配供者的外周血. Orca-T已经获得了美国再生医学高级疗法(RMAT)的认证.S. 目前正在研究用于治疗多种血液恶性肿瘤.

About Orca Bio
Orca Bio is a late-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. 我们的研究疗法旨在提供比标准同种异体干细胞移植更高的存活率和更低的风险, 比如移植物抗宿主病和其他使人衰弱的移植相关毒性. At Orca Bio, 我们不仅希望用健康的血液和免疫系统取代病人的血液和免疫系统, but restore their quality of life. For more information, visit www.orcabio.com and follow Orca Bio on Twitter: @orcabio.

关于大萨克拉门托经济委员会
大萨克拉门托经济委员会是十大网投官方入口首都地区创新增长战略的催化剂. The organization spearheads community-led direction to retain, attract, grow and scale tradable sectors, 在六县区域内发展先进产业，创造就业和投资. 大萨克拉门托代表了地方政府和州政府之间的合作, market leaders, influencers and stakeholders, with the sole mission of driving inclusive economic growth. 大萨克拉门托地区以发现为基础，以领导力为基础，以创新为动力.